Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sutro Biopharma (STRO) Debt to Equity (2017 - 2023)

Sutro Biopharma (STRO) has disclosed Debt to Equity for 7 consecutive years, with $0.03 as the latest value for Q4 2023.

  • Quarterly Debt to Equity fell 63.8% to $0.03 in Q4 2023 from the year-ago period, while the trailing twelve-month figure was $0.03 through Dec 2023, down 63.8% year-over-year, with the annual reading at $0.03 for FY2023, 63.8% down from the prior year.
  • Debt to Equity hit $0.03 in Q4 2023 for Sutro Biopharma, down from $0.06 in the prior quarter.
  • In the past five years, Debt to Equity ranged from a high of $0.29 in Q1 2020 to a low of $0.03 in Q4 2023.
  • Historically, Debt to Equity has averaged $0.1 across 5 years, with a median of $0.09 in 2021.
  • Biggest five-year swings in Debt to Equity: skyrocketed 199.42% in 2019 and later crashed 72.71% in 2021.
  • Year by year, Debt to Equity stood at $0.1 in 2019, then fell by 26.81% to $0.07 in 2020, then surged by 34.51% to $0.1 in 2021, then dropped by 24.61% to $0.07 in 2022, then crashed by 63.8% to $0.03 in 2023.
  • Business Quant data shows Debt to Equity for STRO at $0.03 in Q4 2023, $0.06 in Q3 2023, and $0.07 in Q2 2023.